8-K: STAAR Surgical Updates Merger Proxy Amid Lawsuits

STAAR Surgical Company has supplemented its merger proxy statement with Alcon, addressing stockholder lawsuits and providing additional background on the transaction and financial analyses.

Summary

• STAAR Surgical Company has filed a Form 8-K to supplement its definitive proxy statement related to the proposed merger with Alcon Research, LLC.
• The supplement addresses two individual lawsuits filed by purported stockholders on October 1, 2025, in New York, alleging misrepresentations and omissions in the proxy statement.
• The lawsuits seek an injunction to prevent the merger, rescission or damages if the merger proceeds, and legal fees.
• STAAR believes the lawsuits are without merit but is providing additional disclosures to avoid potential expense and delay.
• The supplement also details the background of the merger, including management changes, outreach to other potential buyers (Party A, B, C), and the 45-day "window shop" period which ended on September 19, 2025, without competing proposals.
• Significant stockholders, Broadwood (27.3% ownership) and Yunqi Capital (5.1% ownership), have publicly announced their opposition to the merger.
• Conversely, Soleus Capital (6% ownership), STAAR's second-largest active stockholder, supports the merger and intends to vote in favor.
• Citi's financial analysis indicated implied per share equity value ranges for STAAR: $16.35 to $23.80 (Selected Public Companies), $17.15 to $30.80 (Selected Precedent Transactions), and $17.70 to $37.50 (Discounted Cash Flow), compared to the merger consideration of $28.00 and the August 1, 2025 closing price of $17.76.

Sentiment

Score: 4

Explanation: The filing indicates significant stockholder opposition and active litigation seeking to block the merger, which introduces substantial uncertainty and risk. While the company believes the claims are without merit and a major stockholder supports the merger, the negative sentiment from large shareholders and legal challenges weigh heavily. The financial analyses show the merger consideration is within or below some valuation ranges, which fuels opposition.

Positives

• The Board, after discussions with management and Citi, concluded that a third party was unlikely to provide greater value for stockholders on a similar timeline as Alcon.
• The 45-day "window shop" period ended on September 19, 2025, without any competing acquisition proposals, despite active exploration by Broadwood.
• Soleus Capital Master Fund, L.P., a beneficial owner of approximately 6% of outstanding shares and STAAR's second-largest active stockholder, supports the merger proposal and intends to vote in favor.
• Citi's financial analysis, particularly the Discounted Cash Flow and Selected Precedent Transactions analyses, showed implied per share equity values that could exceed the $28.00 merger consideration, with a DCF range up to $37.50 and precedent transactions up to $30.80.

Negatives

• Two individual lawsuits have been filed by purported stockholders alleging misrepresentations and omissions in the proxy statement, seeking an injunction against the merger.
• Several purported stockholders sent demand letters alleging similar deficiencies in disclosures.
• Broadwood, a significant stockholder with 27.3% beneficial ownership, intends to vote against the merger proposal and has filed a definitive proxy statement to solicit opposition.
• Yunqi Capital Limited, a beneficial owner of approximately 5.1% of outstanding shares, also announced its opposition to the merger.
• Management noted uncertainty regarding the timing and durability of a recovery in refractive procedure volumes in China, which would impact revenue growth scenarios.
• The Board considered additional risks to STAAR's standalone business plan, including competitive threats, a potential trade war and related tariff risks, and the potential for price controls in China.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Alcon merger agreement or cause the consummation of the proposed transaction to be delayed or fail to occur.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain certain required regulatory approvals or to satisfy any other closing conditions within expected timeframes or at all.
• Disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.
• Uncertainty regarding the timing and durability of a recovery in refractive procedure volumes in China.
• Competitive threats, a potential trade war and related tariff risks, and the potential for price controls in China affecting STAAR's standalone business plan.

Future Outlook

Management noted uncertainty regarding the timing and durability of a recovery in refractive procedure volumes in China, which would impact revenue growth scenarios. The company also faces potential risks from competitive threats, a trade war, and price controls in China. STAAR cannot predict the outcomes of the current lawsuits but believes they are without merit. The company will not necessarily disclose additional similar filings or demands unless new or significantly different allegations arise.

Management Comments

• Management noted that STAAR's expense profile was improved due to the reductions in operational costs, but that there remained uncertainty regarding the timing and durability of a recovery in refractive procedure volumes in China, which would impact revenue growth scenarios.
• STAAR believes that the Matters are without merit, in order to moot plaintiffs disclosure claims and to avoid nuisance, potential expense and delay, and to provide STAAR stockholders with additional information about the Special Meeting and ability of STAAR stockholders to vote thereat, STAAR has determined to voluntarily supplement the Proxy Statement with the below disclosures.

Industry Context

The filing highlights ongoing M&A activity in the medical device and ophthalmology sectors, as evidenced by the precedent transactions analysis (e.g., Alcon/LENSAR, Boston Scientific/Silk Road Medical). It also underscores the significant impact of regional market dynamics, specifically the uncertainty in China's refractive procedure volumes, and broader geopolitical risks like trade wars and price controls, which are critical considerations for global medical technology companies.

Comparison to Industry Standards

• Citi's Selected Public Companies Analysis compared STAAR to peers like SI-BONE, Inc. (EV/2026E Revenue 3.1x), AtriCure, Inc. (2.9x), Carl Zeiss Meditec AG (1.9x), Tandem Diabetes Care, Inc. (0.9x), and RxSight, Inc. (0.7x), with an observed range of 0.7x to 3.1x and a median of 1.9x.
• Citi's Selected Precedent Transactions Analysis included acquisitions such as Alcon Inc.'s acquisition of LENSAR, Inc. ($0.3 billion, EV/LTM Revenue 6.2x), Boston Scientific Corporation's acquisition of Silk Road Medical, Inc. ($1.2 billion, EV/LTM Revenue 6.3x), and Abbott Laboratories' acquisition of Cardiovascular Systems, Inc. ($0.7 billion, EV/LTM Revenue 3.1x), with an observed range of 3.1x to 6.3x and a median of 5.9x.
• The median one-day unaffected stock price premium paid for comparable cash acquisition transactions over $500 million since January 1, 2015, was 26%.

Management Changes

Corporate Governance

Legal Proceedings

• Two individual lawsuits filed by purported stockholders, Smith v. STAAR Surgical Company et al. and Miller v. STAAR Surgical Company et al., in the Supreme Court of the State of New York, County of New York, on October 1, 2025.
• The complaints allege that the Proxy Statement misrepresents and/or omits certain purportedly material information and assert violations of New York common law against STAAR and its Board members.
• Relief sought includes an injunction enjoining the consummation of the Merger, rescission or rescissory damages if the Merger is consummated, costs of the action, including reasonable plaintiffs' attorneys' fees and experts' fees, and other relief.
• Several purported stockholders also sent demand letters alleging similar disclosure deficiencies.
• STAAR believes these matters are without merit but is providing supplemental disclosures to avoid nuisance, potential expense, and delay.

Stakeholder Impact

• Shareholders: Directly impacted by the proposed merger consideration of $28.00 per share, the ongoing litigation, and the upcoming vote on October 23, 2025. Significant shareholders (Broadwood, Yunqi Capital) are opposing the merger, while another (Soleus Capital) supports it, indicating divided sentiment.
• Management & Employees: Potential disruption to ongoing business operations due to the proposed transaction and risks related to retaining and hiring key personnel.
• Customers & Suppliers: Potential impact on relationships due to the proposed transaction.
• Alcon (Acquirer): Faces potential delays and increased costs due to litigation and stockholder opposition, which could affect the timing and certainty of the acquisition.

Next Steps

• Special meeting of STAAR's stockholders to be held on October 23, 2025, to vote upon the proposal to adopt the Merger Agreement.
• STAAR will continue to address the ongoing litigation and stockholder concerns.

Key Dates

Recommendation

The filing presents a mixed bag for investors. While the company is moving forward with the Alcon merger, significant stockholder opposition from major holders like Broadwood and Yunqi Capital, coupled with active lawsuits seeking an injunction, introduces substantial uncertainty and risk. Citi's financial analyses show a range of implied values, with some exceeding the $28.00 merger consideration, which likely fuels the opposition. However, the absence of competing offers during the 'window shop' period and support from another large shareholder (Soleus Capital) suggest the current offer might be the best achievable under the circumstances. Given the legal and shareholder battle, a 'hold' recommendation is prudent. Investors should await the outcome of the stockholder vote and legal proceedings, as these events will significantly clarify the merger's path and potential value realization.

Keywords

STAAR Surgical, Alcon, Merger, SEC Filing, 8-K, Proxy Statement, Stockholder Lawsuits, Corporate Governance, M&A, Ophthalmology, ICL, Refractive Surgery, Financial Analysis, Broadwood, Yunqi Capital, Soleus Capital